Deborah H. Telman's most recent trade in Gilead Sciences, Inc. was a trade of 8,229 Restricted Stock Unit done . Disclosure was reported to the exchange on July 25, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2025 | 8,229 | 21,646 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2025 | 8,229 | 46,544 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 116.20 per share. | 25 Jul 2025 | 3,823 | 42,721 (0%) | 0% | 116.2 | 444,233 | Common Stock |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2025 | 514 | 29,875 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2025 | 514 | 38,315 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2025 | 1,313 | 30,389 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2025 | 1,313 | 38,231 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 110.09 per share. | 10 Jun 2025 | 430 | 37,801 (0%) | 0% | 110.1 | 47,339 | Common Stock |
| Atricure Inc | Deborah H. Telman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 5,401 | 22,184 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Apr 2025 | 514 | 37,076 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Apr 2025 | 514 | 31,702 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.17 per share. | 25 Apr 2025 | 158 | 36,918 (0%) | 0% | 103.2 | 16,301 | Common Stock |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 33,940 | 33,940 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 7,680 | 32,216 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 3,343 | 37,692 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 3,343 | 24,356 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.21 per share. | 10 Mar 2025 | 1,130 | 36,562 (0%) | 0% | 117.2 | 132,447 | Common Stock |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 12,371 | 34,011 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2025 | 515 | 21,827 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2025 | 515 | 27,879 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 93.07 per share. | 25 Jan 2025 | 187 | 21,640 (0%) | 0% | 93.1 | 17,404 | Common Stock |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 639 | 28,394 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 639 | 21,618 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.34 per share. | 10 Dec 2024 | 306 | 21,312 (0%) | 0% | 92.3 | 28,256 | Common Stock |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Oct 2024 | 514 | 29,033 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Oct 2024 | 514 | 21,221 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 89.00 per share. | 25 Oct 2024 | 242 | 20,979 (0%) | 0% | 89 | 21,538 | Common Stock |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 639 | 21,014 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 639 | 29,547 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.44 per share. | 10 Sep 2024 | 307 | 20,707 (0%) | 0% | 81.4 | 25,002 | Common Stock |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2024 | 8,230 | 20,375 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2024 | 8,230 | 30,186 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 76.51 per share. | 25 Jul 2024 | 2,917 | 11,631 (0%) | 0% | 76.5 | 223,180 | Common Stock |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2024 | 514 | 12,145 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2024 | 514 | 38,416 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 638 | 14,752 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 638 | 38,930 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.25 per share. | 10 Jun 2024 | 204 | 14,548 (0%) | 0% | 65.3 | 13,311 | Common Stock |
| Atricure Inc | Deborah H. Telman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 7,788 | 16,783 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Apr 2024 | 515 | 39,568 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Apr 2024 | 515 | 14,272 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.27 per share. | 25 Apr 2024 | 158 | 14,114 (0%) | 0% | 65.3 | 10,313 | Common Stock |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 54,980 | 54,980 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 10,815 | 40,083 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 2,555 | 14,603 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 2,555 | 29,268 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.12 per share. | 10 Mar 2024 | 846 | 13,757 (0%) | 0% | 75.1 | 63,552 | Common Stock |
| Gilead Sciences | Deborah Telman H. | EVP, Corporate Affairs & GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 4,646 | 11,728 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2024 | 514 | 7,276 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Telman H. Deborah | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2024 | 514 | 31,823 | - | - | Restricted Stock Unit | |
| Gilead Sciences | H. Deborah Telman | EVP, Corporate Affairs & GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.23 per share. | 25 Jan 2024 | 194 | 7,082 (0%) | 0% | 80.2 | 15,565 | Common Stock |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Oct 2023 | 514 | 32,337 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Oct 2023 | 514 | 7,005 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.39 per share. | 25 Oct 2023 | 243 | 6,762 (0%) | 0% | 78.4 | 19,049 | Common Stock |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2023 | 8,231 | 34,909 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2023 | 8,231 | 8,607 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.23 per share. | 25 Jul 2023 | 4,174 | 4,433 (0%) | 0% | 77.2 | 322,358 | Common Stock |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2023 | 2,058 | 6,491 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2023 | 2,058 | 32,851 | - | - | Restricted Stock Unit | |
| Atricure Inc | Deborah H. Telman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 3,186 | 8,995 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 46,605 | 46,605 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 10,220 | 43,140 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Deborah H. Telman | EVP, Corporate Affairs & GC | Grant, award, or other acquisition of securities at price $ 56.38 per share. | 15 Feb 2023 | 376 | 376 (0%) | 0% | 56.4 | 21,199 | Common Stock |
| Atricure Inc | Deborah H. Telman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 3,564 | 5,809 (0%) | 0% | 0 | Common Stock | |
| Organon & Co. | Deborah H. Telman | EVP GC & Corporate Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 4,431 | 8,987 | - | - | Common Stock | |
| Organon & Co. | Deborah H. Telman | EVP GC & Corporate Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 4,431 | 4,431 | - | - | Restricted Stock Units | |
| Organon & Co. | Deborah H. Telman | EVP GC & Corporate Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.44 per share. | 04 May 2022 | 1,299 | 7,688 | - | 32.4 | 42,140 | Common Stock |
| Organon & Co. | Deborah H. Telman | Gen Counsel & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 39,682 | 39,682 | - | - | Stock Option (right to buy) | |
| Organon & Co. | Deborah H. Telman | Gen Counsel & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 12,882 | 12,882 | - | - | Restricted Stock Units | |
| Organon & Co. | Deborah H. Telman | Gen Counsel & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 22,321 | 22,321 | - | - | Stock Option (Right to Buy) | |
| Organon & Co. | Deborah H. Telman | EVP GC & Corporate Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.63 per share. | 05 Aug 2021 | 6,445 | 6,445 | - | 28.6 | 184,520 | Common Stock |
| Organon & Co. | Deborah H. Telman | EVP GC & Corporate Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2021 | 6,445 | 12,892 | - | - | Restricted Stock Units | |
| Organon & Co. | Deborah H. Telman | EVP GC & Corporate Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.63 per share. | 05 Aug 2021 | 1,889 | 4,556 | - | 28.6 | 54,082 | Common Stock |
| Atricure Inc | Deborah H. Telman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 2,245 | 2,245 (0%) | 0% | 0 | Common Stock | |
| Organon & Co. | Deborah H. Telman | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 103,095 | 103,095 | - | - | Stock Option (Right to Buy) | |
| Organon & Co. | Deborah H. Telman | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 19,337 | 19,337 | - | - | Restricted Stock Units | |
| Organon & Co. | Deborah H. Telman | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 17,624 | 17,624 | - | - | Restricted Stock Units | |
| Organon & Co. | Deborah H. Telman | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 13,296 | 13,296 | - | - | Restricted Stock Units |